Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aurinia Pharm Ord
(NQ:
AUPH
)
5.090
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
5.090
Bid (Size)
4.870 (1)
Ask (Size)
5.300 (4)
Prev. Close
5.090
Today's Range
5.090 - 5.090
52wk Range
4.710 - 12.43
Shares Outstanding
128,395,927
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 16, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
April 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Performance
YTD
-41.76%
-41.76%
1 Month
+2.00%
+2.00%
3 Month
-36.77%
-36.77%
6 Month
-32.31%
-32.31%
1 Year
-52.65%
-52.65%
More News
Read More
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
April 09, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
February 29, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Earnings Outlook For Aurinia Pharmaceuticals
February 14, 2024
Via
Benzinga
Aurinia to Participate in Upcoming Investor Healthcare Conferences
February 27, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
February 22, 2024
Via
Benzinga
Aurinia Pharmaceuticals Finds No Buyer After Strategic Business Review, Launches Stock Buyback
February 15, 2024
Via
Benzinga
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
February 15, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 15, 2024
Via
Benzinga
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
February 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
What's Going On With Aurinia Pharmaceuticals Stock?
January 05, 2024
Via
Benzinga
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
January 05, 2024
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
December 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
What's Going On With Aurinia Pharmaceuticals Stock?
November 20, 2023
Via
Benzinga
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan
November 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
November 07, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
November 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra'
October 30, 2023
Via
Benzinga
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
October 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
October 19, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
October 13, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
September 21, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.